Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma
Background and Aims A large-scale multicenter study validated aldo–keto reductase 1B10 (AKR1B10) as a new serum marker of hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic value of serum AKR1B10 in HCC. Methods 273 naïve HCC patients enrolled for serum AKR1B10 tests were fo...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology 2023-10, Vol.58 (10), p.1030-1042 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1042 |
|---|---|
| container_issue | 10 |
| container_start_page | 1030 |
| container_title | Journal of gastroenterology |
| container_volume | 58 |
| creator | Xie, Chenglin Ye, Xu Zeng, Li Zeng, Xi Cao, Deliang |
| description | Background and Aims
A large-scale multicenter study validated aldo–keto reductase 1B10 (AKR1B10) as a new serum marker of hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic value of serum AKR1B10 in HCC.
Methods
273 naïve HCC patients enrolled for serum AKR1B10 tests were followed up for 2 years. Survival and clinical data were collected. Kaplan–Meier survival analysis and log-rank tests were used to estimate correlation of patient survival with serum AKR1B10. Univariate and multivariate COX regression analyses were used to evaluate the prognostic value of serum AKR1B10 level independently or in combination with other clinicopathological factors. α-fetoprotein (AFP) was analyzed in parallel for comparison.
Results
Serum AKR1B10 associated with tumor stage (
p =
0.012), size (
p =
0.004), primary tumor number (
p =
0.019), and Child–Pugh classification (
p =
0.003). HCC patients with a high level of serum AKR1B10 (≥ 267.9 pg/ml) had median survival (MS) of 25 months (95% confidence interval [CI] 20.788–29.212) vs. MS of 34 months (CI 28.911–39.089) in patients with normal serum AKR1B10 (
p |
| doi_str_mv | 10.1007/s00535-023-02011-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2854431048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890365139</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-31f94d57a06df252d0d3b855bc4812c06692ee69a4f60e63690e0ae1908a26133</originalsourceid><addsrcrecordid>eNp9kEtLxDAQx4Mo7rr6BTxIwYuX6kxebY7r4gsF8XUO2TbVLn2syXbBb29qVwUPHoaByW_-GX6EHCKcIkBy5gEEEzFQFgoQY7VFxsjDSChKt8kYFOcxYsJHZM_7BQAyEOkuGbFEACiajMnDk3VdHU1vH_EcITI-Mk1UNnmZmVXroraIuqYw69aZeWUj37l1uTZVP3-zy4Bktqq6yrgoMy4rm7Y2-2SnMJW3B5s-IS-XF8-z6_ju_upmNr2LM6bUKmZYKJ6LxIDMCypoDjmbp0LMM54izUBKRa2VyvBCgpVMKrBgLCpIDZXI2IScDLlL17531q90Xfr-HNPYtvOapoJzhsDTgB7_QRdt55pwXaAUMCmQqUDRgcpc672zhV66sjbuQyPoXrgehOsgXH8J1_3S0Sa6m9c2_1n5NhwANgA-PDWv1v3-_U_sJ4UDiN8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890365139</pqid></control><display><type>article</type><title>Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma</title><source>SpringerLink Journals - AutoHoldings</source><creator>Xie, Chenglin ; Ye, Xu ; Zeng, Li ; Zeng, Xi ; Cao, Deliang</creator><creatorcontrib>Xie, Chenglin ; Ye, Xu ; Zeng, Li ; Zeng, Xi ; Cao, Deliang</creatorcontrib><description>Background and Aims
A large-scale multicenter study validated aldo–keto reductase 1B10 (AKR1B10) as a new serum marker of hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic value of serum AKR1B10 in HCC.
Methods
273 naïve HCC patients enrolled for serum AKR1B10 tests were followed up for 2 years. Survival and clinical data were collected. Kaplan–Meier survival analysis and log-rank tests were used to estimate correlation of patient survival with serum AKR1B10. Univariate and multivariate COX regression analyses were used to evaluate the prognostic value of serum AKR1B10 level independently or in combination with other clinicopathological factors. α-fetoprotein (AFP) was analyzed in parallel for comparison.
Results
Serum AKR1B10 associated with tumor stage (
p =
0.012), size (
p =
0.004), primary tumor number (
p =
0.019), and Child–Pugh classification (
p =
0.003). HCC patients with a high level of serum AKR1B10 (≥ 267.9 pg/ml) had median survival (MS) of 25 months (95% confidence interval [CI] 20.788–29.212) vs. MS of 34 months (CI 28.911–39.089) in patients with normal serum AKR1B10 (
p <
0.001). Univariate and multivariate COX regression analyses showed that serum AKR1B10 level was an unfavorable prognostic marker of HCC independently (HR 1.830, 95% CI 1.312–2.552;
p <
0.001) or in combination with other clinical factors (HR 1.883, 95% CI 1.264–2.806;
p =
0.002), such as TNM stage, tumor size and portal invasion. In the same cohort of HCC patients, AFP exhibited prognostic value at a cut-off of 400 ng/ml, but not at 20 ng/ml and 200 ng/ml.
Conclusions
Serum AKR1B10 is a new prognostic marker of HCC, better than AFP.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-023-02011-9</identifier><identifier>PMID: 37500927</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Abdominal Surgery ; Biliary Tract ; Colorectal Surgery ; Gastroenterology ; Hepatocellular carcinoma ; Hepatology ; Liver cancer ; Medicine ; Medicine & Public Health ; Original Article―Liver ; Pancreas ; Regression analysis ; Surgical Oncology ; Survival ; Survival analysis ; Tumors ; α-Fetoprotein</subject><ispartof>Journal of gastroenterology, 2023-10, Vol.58 (10), p.1030-1042</ispartof><rights>Japanese Society of Gastroenterology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. Japanese Society of Gastroenterology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-31f94d57a06df252d0d3b855bc4812c06692ee69a4f60e63690e0ae1908a26133</citedby><cites>FETCH-LOGICAL-c399t-31f94d57a06df252d0d3b855bc4812c06692ee69a4f60e63690e0ae1908a26133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-023-02011-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-023-02011-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37500927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xie, Chenglin</creatorcontrib><creatorcontrib>Ye, Xu</creatorcontrib><creatorcontrib>Zeng, Li</creatorcontrib><creatorcontrib>Zeng, Xi</creatorcontrib><creatorcontrib>Cao, Deliang</creatorcontrib><title>Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Background and Aims
A large-scale multicenter study validated aldo–keto reductase 1B10 (AKR1B10) as a new serum marker of hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic value of serum AKR1B10 in HCC.
Methods
273 naïve HCC patients enrolled for serum AKR1B10 tests were followed up for 2 years. Survival and clinical data were collected. Kaplan–Meier survival analysis and log-rank tests were used to estimate correlation of patient survival with serum AKR1B10. Univariate and multivariate COX regression analyses were used to evaluate the prognostic value of serum AKR1B10 level independently or in combination with other clinicopathological factors. α-fetoprotein (AFP) was analyzed in parallel for comparison.
Results
Serum AKR1B10 associated with tumor stage (
p =
0.012), size (
p =
0.004), primary tumor number (
p =
0.019), and Child–Pugh classification (
p =
0.003). HCC patients with a high level of serum AKR1B10 (≥ 267.9 pg/ml) had median survival (MS) of 25 months (95% confidence interval [CI] 20.788–29.212) vs. MS of 34 months (CI 28.911–39.089) in patients with normal serum AKR1B10 (
p <
0.001). Univariate and multivariate COX regression analyses showed that serum AKR1B10 level was an unfavorable prognostic marker of HCC independently (HR 1.830, 95% CI 1.312–2.552;
p <
0.001) or in combination with other clinical factors (HR 1.883, 95% CI 1.264–2.806;
p =
0.002), such as TNM stage, tumor size and portal invasion. In the same cohort of HCC patients, AFP exhibited prognostic value at a cut-off of 400 ng/ml, but not at 20 ng/ml and 200 ng/ml.
Conclusions
Serum AKR1B10 is a new prognostic marker of HCC, better than AFP.</description><subject>Abdominal Surgery</subject><subject>Biliary Tract</subject><subject>Colorectal Surgery</subject><subject>Gastroenterology</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatology</subject><subject>Liver cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article―Liver</subject><subject>Pancreas</subject><subject>Regression analysis</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Tumors</subject><subject>α-Fetoprotein</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kEtLxDAQx4Mo7rr6BTxIwYuX6kxebY7r4gsF8XUO2TbVLn2syXbBb29qVwUPHoaByW_-GX6EHCKcIkBy5gEEEzFQFgoQY7VFxsjDSChKt8kYFOcxYsJHZM_7BQAyEOkuGbFEACiajMnDk3VdHU1vH_EcITI-Mk1UNnmZmVXroraIuqYw69aZeWUj37l1uTZVP3-zy4Bktqq6yrgoMy4rm7Y2-2SnMJW3B5s-IS-XF8-z6_ju_upmNr2LM6bUKmZYKJ6LxIDMCypoDjmbp0LMM54izUBKRa2VyvBCgpVMKrBgLCpIDZXI2IScDLlL17531q90Xfr-HNPYtvOapoJzhsDTgB7_QRdt55pwXaAUMCmQqUDRgcpc672zhV66sjbuQyPoXrgehOsgXH8J1_3S0Sa6m9c2_1n5NhwANgA-PDWv1v3-_U_sJ4UDiN8</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Xie, Chenglin</creator><creator>Ye, Xu</creator><creator>Zeng, Li</creator><creator>Zeng, Xi</creator><creator>Cao, Deliang</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20231001</creationdate><title>Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma</title><author>Xie, Chenglin ; Ye, Xu ; Zeng, Li ; Zeng, Xi ; Cao, Deliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-31f94d57a06df252d0d3b855bc4812c06692ee69a4f60e63690e0ae1908a26133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdominal Surgery</topic><topic>Biliary Tract</topic><topic>Colorectal Surgery</topic><topic>Gastroenterology</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatology</topic><topic>Liver cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article―Liver</topic><topic>Pancreas</topic><topic>Regression analysis</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Tumors</topic><topic>α-Fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xie, Chenglin</creatorcontrib><creatorcontrib>Ye, Xu</creatorcontrib><creatorcontrib>Zeng, Li</creatorcontrib><creatorcontrib>Zeng, Xi</creatorcontrib><creatorcontrib>Cao, Deliang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xie, Chenglin</au><au>Ye, Xu</au><au>Zeng, Li</au><au>Zeng, Xi</au><au>Cao, Deliang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>58</volume><issue>10</issue><spage>1030</spage><epage>1042</epage><pages>1030-1042</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Background and Aims
A large-scale multicenter study validated aldo–keto reductase 1B10 (AKR1B10) as a new serum marker of hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic value of serum AKR1B10 in HCC.
Methods
273 naïve HCC patients enrolled for serum AKR1B10 tests were followed up for 2 years. Survival and clinical data were collected. Kaplan–Meier survival analysis and log-rank tests were used to estimate correlation of patient survival with serum AKR1B10. Univariate and multivariate COX regression analyses were used to evaluate the prognostic value of serum AKR1B10 level independently or in combination with other clinicopathological factors. α-fetoprotein (AFP) was analyzed in parallel for comparison.
Results
Serum AKR1B10 associated with tumor stage (
p =
0.012), size (
p =
0.004), primary tumor number (
p =
0.019), and Child–Pugh classification (
p =
0.003). HCC patients with a high level of serum AKR1B10 (≥ 267.9 pg/ml) had median survival (MS) of 25 months (95% confidence interval [CI] 20.788–29.212) vs. MS of 34 months (CI 28.911–39.089) in patients with normal serum AKR1B10 (
p <
0.001). Univariate and multivariate COX regression analyses showed that serum AKR1B10 level was an unfavorable prognostic marker of HCC independently (HR 1.830, 95% CI 1.312–2.552;
p <
0.001) or in combination with other clinical factors (HR 1.883, 95% CI 1.264–2.806;
p =
0.002), such as TNM stage, tumor size and portal invasion. In the same cohort of HCC patients, AFP exhibited prognostic value at a cut-off of 400 ng/ml, but not at 20 ng/ml and 200 ng/ml.
Conclusions
Serum AKR1B10 is a new prognostic marker of HCC, better than AFP.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>37500927</pmid><doi>10.1007/s00535-023-02011-9</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-1174 |
| ispartof | Journal of gastroenterology, 2023-10, Vol.58 (10), p.1030-1042 |
| issn | 0944-1174 1435-5922 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2854431048 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Abdominal Surgery Biliary Tract Colorectal Surgery Gastroenterology Hepatocellular carcinoma Hepatology Liver cancer Medicine Medicine & Public Health Original Article―Liver Pancreas Regression analysis Surgical Oncology Survival Survival analysis Tumors α-Fetoprotein |
| title | Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A16%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20AKR1B10%20as%20an%20indicator%20of%20unfavorable%20survival%20of%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Xie,%20Chenglin&rft.date=2023-10-01&rft.volume=58&rft.issue=10&rft.spage=1030&rft.epage=1042&rft.pages=1030-1042&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-023-02011-9&rft_dat=%3Cproquest_cross%3E2890365139%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890365139&rft_id=info:pmid/37500927&rfr_iscdi=true |